Allergan Generic Drug Pricing Securities Litigation: Investors Pursue Fraud Claims Based on Concealed Price-Fixing Conspiracy

Kessler Topaz serves as co-lead counsel in a securities fraud class action brought on behalf of Allergan plc shareholders, based on the company’s participation in an industry-wide conspiracy to fix the prices of generic drugs.  Shareholders allege that notwithstanding Allergan’s prominent role in this illicit price-fixing scheme, the company repeatedly misrepresented to investors that it was not engaged in anticompetitive conduct—even as the company became ensnared in an investigation by the U.S. Department of Justice and 46 state attorneys general.

On August 6, 2019, the Honorable Katherine S. Hayden of the U.S. District Court for the District of New Jersey issued a lengthy opinion denying defendants’ motions to dismiss the complaint and sustaining investors’ claims in full.  The case is now in discovery.   

D 610.822.2220
D 484.270.1413
D 484.654.2883
D 484.270.1456
D 484.270.1423
D 484.270.1445